ABVX 주가 차트
ABVX 재무
ABIVAX Société Anonyme
$129.69
-2.21%
$-2.93
종가: Jun 01, 16:00:00 GMT-4
$97.01
-25.19%
$-32.67
애프터마켓: Jun 01, 20:00:00 GMT-4
뒤로
ABIVAX Société Anonyme (ABVX) 재무
주요 통계
이전 종가
$132.63
시가
$134.14
일일 범위
$97.01 - $134.14
52주 범위
$5.59 - $148.83
거래량
1.3M
평균 거래량
952.8K
배당수익률
--
EPS(TTM)
-5.67
시가총액
$7.6B
Abivax SA란 무엇인가요?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
